Compounds > vidarabine
Page last updated: 2024-08-22

vidarabine and Anemia, Aplastic

vidarabine has been researched along with Anemia, Aplastic in 85 studies

Research

Studies (85)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's37 (43.53)29.6817
2010's39 (45.88)24.3611
2020's9 (10.59)2.80

Authors

AuthorsStudies
Chen, J; Cheng, H; Gao, L; Hu, X; Luo, Y; Tang, G; Wang, J; Yang, D; Yang, J; Zhang, W1
Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP1
Aotsuka, N; Hangaishi, A; Hoshino, T; Kako, S; Kanda, Y; Kato, J; Kobayashi, T; Matsumoto, K; Mori, T; Najima, Y; Okamoto, S; Onizuka, M; Shimizu, H; Shono, K; Tachibana, T; Tanaka, M; Tsukamoto, S; Usuki, K; Watanabe, R; Yamazaki, E; Yano, S1
Cai, Y; Jiang, J; Wan, L; Wang, C; Yang, J1
Atsuta, Y; Fujita, N; Goto, H; Inoue, M; Kato, K; Kawaguchi, H; Kobayashi, R; Koh, K; Kojima, S; Kudo, K; Miyamura, T; Okada, K; Okamoto, Y; Suzuki, R; Takahashi, Y; Watanabe, K; Yabe, H; Yabe, M; Yoshida, N1
Cho, BS; Cho, SG; Eom, KS; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yoon, JH1
Bruce, AAK; Desai, S; Guilcher, GMT; Le, D; Leaker, MT; Lewis, V; Shah, RM; Steele, M; Truong, TH; Wright, NAM1
Ahmed, P; Anwer, F; Chaudhry, QUN; Farhan, M; Ghafoor, T; Humayun, S; Iftikhar, R; Khan, MA; Khattak, TA; Mahmood, SK; Rehman, J; Risalat, A; Satti, HS; Satti, TM; Shahbaz, N; Shamshad, GU; Wahab, A1
Ahmed, P; Ansar, I; Anwer, F; Ashraf, R; Chaudhry, QUN; Farhan, M; Ghafoor, T; Iftikhar, R; Khan, M; Khan, MA; Khattak, TA; Mahmood, SK; Marsh, J; Neupane, K; Rafae, A; Rehman, J; Satti, TM; Shahbaz, N; Shamshad, GU1
Abraham, A; Abubacker, FN; Devasia, AJ; George, B; Korula, A; Kulkarni, U; Lakshmi, KM; Lionel, S; Mathews, V; Selvarajan, S; Sindhuvi, E1
Ahmed, SO; Alahmari, A; Alfraih, F; Alhakim, A; Alhayli, S; Aljurf, M; Almohareb, F; Alsadi, H; Alshaibani, A; Alsharif, F; Alshomar, A; Alzahrani, H; Assiri, A; Babiker, F; Balbaid, A; Chaudhri, N; El Fakih, R; Elhassan, T; Ghabashi, E; Hanbali, A; Kotb, A; Rasheed, W; Samarkandi, H; Shaheen, M1
Boulad, F; Curran, K; Kernan, NA; O'Reilly, RJ; Prockop, SE; Ruggiero, J; Scaradavou, A; Takpradit, C; Zakak, N1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Park, SS; Yoon, JH1
Chiba, S; Fukuda, T; Kako, S; Kanda, Y; Kondo, Y; Kurokawa, M; Miyamoto, T; Miyamura, K; Nagafuji, K; Nakao, S; Ohashi, Y; Okoshi, Y; Oshima, K; Takaue, Y; Taniguchi, S; Uchida, N1
Cho, B; Chung, NG; Jang, PS; Jeong, DC; Kim, HK; Lee, JW1
Frangoul, H; Hussein, AA1
Barrett, J; Childs, RW; Cook, L; Donohue, T; Geller, N; Khuu, H; Kurlander, R; Leitman, S; Pantin, J; Ramos, C; Shah, AA; Stroncek, D; Tian, X; Young, NS1
Akahoshi, Y; Ashizawa, M; Ishihara, Y; Kako, S; Kanda, J; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, S; Nakano, H; Nakasone, H; Nishida, J; Sakamoto, K; Sato, M; Tanihara, A; Terasako, K; Ugai, T; Wada, H; Yamasaki, R; Yamazaki, R1
Chen, T; Fang, J; Huang, Y; Lin, X; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B1
Bae, SH; Choi, JH; Joo, YD; Jung, CW; Kim, BS; Kim, H; Kim, HJ; Kim, I; Kim, MK; Kim, SH; Kwak, JY; Lee, KH; Lee, WS; Oh, S; Park, JH; Shin, HJ; Sohn, SK; Won, JH1
Chen, T; Du, Q; Huang, Y; Lin, X; Lu, Z; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B1
Baker, KS; Burroughs, LM; Deeg, HJ; Delaney, C; Domm, J; Englund, JA; Flowers, ME; Giller, RH; Nemecek, ER; Rawlings, DJ; Shimamura, A; Skoda-Smith, S; Storb, R; Storer, BE; Talano, JA; Thakar, MS; Torgerson, TR; Woolfrey, AE1
Chen, HR; Guo, Z; He, XP; Liu, XD; Lou, JX; Zhang, Y1
Hashida, R; Kato, J; Kikuchi, T; Koda, Y; Kohashi, S; Mori, T; Okamoto, S; Saburi, M; Toyama, T; Yamanaka, S; Yamane, Y1
Chen, F; Chen, S; Fu, Z; Han, Y; Jin, S; Jin, Z; Liu, L; Ma, X; Miao, M; Qiu, H; Sun, A; Tang, X; Wang, X; Wu, D; Zhang, X1
Huang, P; Li, S; Liu, Q; Wang, J; Xu, N; Zhang, F; Zhao, X1
Ai, HS; Dong, Z; Guo, M; Hu, KX; Huang, XM; Huang, YJ; Liu, ZQ; Qiao, JH; Sun, QY; Wang, SF; Wang, Y; Yu, CL; Zuo, HL1
Chen, J; Ding, L; Li, B; Li, Q; Luo, C; Wang, J1
Chang, W; Chen, F; Fu, C; Jin, Z; Ma, X; Miao, M; Qiu, H; Ruan, C; Sun, A; Tang, X; Wu, D; Xue, S1
Ichinohe, T; Iida, H; Kako, S; Kanamori, H; Kanda, Y; Kato, C; Koh, H; Maeda, T; Mori, T; Nakao, S; Onishi, Y; Onizuka, M; Ozawa, Y; Suzuki, R; Yamazaki, H1
Ahn, HS; Cho, B; Chung, NG; Hong, KT; Im, HJ; Jung, HJ; Kang, HJ; Kim, H; Kim, HK; Kim, SY; Koh, KN; Koo, HH; Lee, JH; Lee, JW; Lee, SH; Lee, YH; Lim, YJ; Lim, YT; Park, JA; Park, JE; Park, KD; Park, SK; Ryu, KH; Seo, JJ; Shin, HY; Sung, KW; Yoo, ES; Yoo, KH1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH1
Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y1
Führer, M1
Ativitavas, T; Jootar, S; Niparuck, P; Ungkanont, A1
du Toit, C; McDonald, A; Novitzky, N; Thomas, V1
Higuchi, T; Kako, S; Kanda, Y; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sato, M; Tanaka, Y; Tanihara, A; Terasako, K; Yamazaki, R1
Eyzaguirre-Zapata, R; Gómez-Almaguer, D; González-Carrillo, ML; Gutiérrez-Aguirre, CH; Gutiérrez-Riveroll, KI; Priesca-Marin, M; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ1
Aljurf, M; Anderlini, P; Bacigalupo, A; Marsh, J; Maury, S; Oneto, R; Passweg, JR; Socié, G1
Cao, TM; Franke, GN; Gyurkocza, B; Hoppe, R; Lange, T; Leisenring, W; Maloney, DG; Negrin, RS; Sandmaier, BM; Shizuru, JA; Sorror, M; Storb, RF1
Aoyama, M; Hashimoto, S; Itagaki, N; Iwanaga, T; Kawamura, M; Kazuta, T; Matsuda, M; Rai, S; Yamairi, N1
Bacigalupo, A; Brune, M; Cesaro, S; Lanino, E; Locasciulli, A; Locatelli, F; Marsh, J; Oneto, R; Passweg, J; Prete, A; Shimoni, A; Socie', G; Van Lint, MT1
Ahn, HS; Cho, B; Chung, NG; Im, HJ; Kang, HJ; Kim, HK; Kim, SY; Koo, HH; Lee, YH; Lim, YT; Park, JE; Park, SK; Seo, JJ; Shin, HY; Sung, KW; Yoo, KH1
Ahmed, S; Al-Anazi, K; Al-Mohareb, F; Al-Sharif, F; Al-Zahrani, H; Aljurf, M; Bakr, M; Chaudhri, N; Elhassan, T; Elkum, N; Hussain, F; Ibrahim, K; Mohamed, S; Nassar, A; Nurgat, Z; Patel, M; Rasheed, W; Saleh, AJ1
Acholonu, SA; Anderlini, P; Bassett, RE; Champlin, RE; Giralt, SA; Okoroji, GJ; Popat, UR; Qazilbash, MH; Shpall, EJ; Worth, LL1
Kato, S; Koike, T; Morimoto, T; Shimizu, T; Suganuma, E; Sugiyama, N; Takakura, H; Yabe, H; Yabe, M1
Bansal, D; Gautam, V; Marwaha, N; Marwaha, RK; Oberoi, S; Sharma, RR1
Gupta, V; Hayden, J; Ho, AY; Ireland, RM; Islam, MS; Koh, MB; Lim, Z; Marks, DI; Marsh, JC; Mufti, GJ; Pagliuca, A; Potter, V; Russell, N1
Choi, ES; Im, HJ; Jang, S; Kim, BE; Koh, KN; Kwon, SW; Park, CJ; Seo, JJ1
Ding, KY; Geng, LQ; Liu, HL; Sun, ZM; Tang, BI; Tong, J; Wang, XB; Wang, ZY1
Bae, SH; Hyun, MS; Joo, YD; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Park, JH; Ryoo, HM1
Adams, RH; Anderlini, P; Antin, JH; Arai, S; Carter, SL; Confer, DL; Deeg, HJ; Difronzo, NL; Eapen, M; Ewell, M; Gersten, ID; Horowitz, MM; Horwitz, M; Leifer, ES; McCarty, JM; Nakamura, R; Pulsipher, MA; Tolar, J1
Ramos, CA1
Aljurf, M; Maury, S1
du Toit, C; Novitzky, N; Thomas, V1
Fukiya, E; Kimura, S; Kobayashi, Y; Kuroda, J; Murotani, Y; Ozawa, M; Terao, K; Yoshikawa, T1
Nakao, S1
Ambulkar, I; Parikh, PM; Saikia, T1
Ahn, HS; Choi, HS; Kang, HJ; Shin, HY1
Ball, SE; Freires, M; Gordon-Smith, EC; Gupta, V; Marsh, JC; Ortin, M; Sage, D1
Benesch, M; Lackner, H; Schwinger, W; Sykora, KW; Urban, C1
Abe, Y; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Tachikawa, Y1
Choi, SJ; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, YS; Ryu, SG; Seol, M1
Benesch, M; Dornbusch, HJ; Lackner, H; Schwinger, W; Sovinz, P; Urban, C1
Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M1
Bacigalupo, A; Cesaro, S; Lanino, E; Locasciulli, A; Locatelli, F; Marsh, J; Maury, S; Passweg, J; Prete, A; Socié, G1
Rzepecki, P; Sarosiek, T; Szczylik, C1
Kami, M; Kusumi, E; Masuoka, K; Miura, Y; Murashige, N; Tachibana, S; Taniguchi, S; Yoshimura, M1
Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-Rangel, JD; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Rivas-Vera, S; Ruiz-Argüelles, GJ; Sobrevilla-Calvo, P; Vela-Ojeda, J1
Choudhry, VP; Chowdhary, DR; Kumar, R; Mahapatra, M; Mehra, NK; Mishra, P; Narendra, AM; Pillai, L; Prem, S; Saxena, R; Seth, T1
Barrett, AJ; Childs, RW; Dorrance, C; Espinoza-Delgado, I; Geller, N; Igarashi, T; Lundqvist, A; McCoy, JP; Srinivasan, R; Takahashi, Y; Young, NS1
Abdul-Hai, A; Ackerstein, A; Aker, M; Bitan, M; Gesundheit, B; Lvovich, A; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Tsirigotis, PD; Yoffe, L; Zilberman, I1
Goto, K; Hara, T; Hattori, S; Ichino, K; Nakamura, K; Nomura, A; Ohga, S; Takada, H1
Cutting, R; Edbrooke, D; El-Ghariani, K; Ezaydi, Y; Snowden, JA; Stamps, R1
Chuah, CT; Goh, YT; Hwang, WY; Koh, LP; Koh, MB; Linn, YC; Loh, YS; Ng, HJ; Ng, HY; Tan, DC; Tan, KW; Tan, PH1
Bianchi, M; Castiglioni, MG; Mechelli, S; Pandolfo, C; Scatena, P1
Lazarevic, V; Wahlin, A1
Aschan, J; Barkholt, L; Dahllöf, G; Gustafsson, B; Hassan, Z; Ljungman, P; Mattsson, J; Omazic, B; Remberger, M; Ringdén, O; Svahn, BM; Svenberg, P; Uzunel, M; Winiarski, J1
Chuhjo, T; Kondo, Y; Kotani, T; Nakao, S; Ohtake, S; Okumura, H; Ozaki, J; Sugimori, C; Sugimori, N; Takami, A; Ueda, M; Yamaguchi, M; Yamazaki, H1
Chandy, M; George, B; Kavitha, ML; Mathews, V; Srivastava, A; Viswabandya, A2
Balère-Appert, ML; Boiron, JM; Bordigoni, P; Chir, Z; Galambrun, C; Kanold, J; Maillard, N; Marie-Cardine, A; Maury, S; Milpied, N; Socié, G; Yakouben, K1
Balashov, D; Filimonov, A; Maschan, A; Maschan, M; Novichkova, G; Shelikhova, L; Shipicina, I; Skorobogatova, E; Skvortsova, Y; Trakhtman, P1
Chan, KW; Chik, KW; Jeha, S; Li, CK; Shing, MK; Worth, LL; Yuen, PM1
Bacigalupo, A; Endo, T; Fujimoto, K; Koike, T; Nakao, S; Nishio, M; Sakai, T; Sawada, K; Takashima, H1

Reviews

4 review(s) available for vidarabine and Anemia, Aplastic

ArticleYear
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies.
    Blood reviews, 2021, Volume: 47

    Topics: Age Factors; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclosporine; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Methotrexate; Risk Factors; Transplantation Conditioning; Unrelated Donors; Vidarabine

2021
Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia.
    Bone marrow transplantation, 2008, Volume: 42 Suppl 2

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Child; Child, Preschool; Donor Selection; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Living Donors; Lymphocyte Depletion; Male; Peripheral Blood Stem Cell Transplantation; Risk Adjustment; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning.
    Bone marrow transplantation, 2013, Volume: 48, Issue:2

    Topics: Adult; Anemia, Aplastic; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine

2013
[Non-myeloablative stem cell transplantation for non-malignant hematologic disorders].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Hemochromatosis; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2003

Trials

15 trial(s) available for vidarabine and Anemia, Aplastic

ArticleYear
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
    American journal of hematology, 2020, Volume: 95, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2020
Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:10

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2020
Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
    American journal of hematology, 2013, Volume: 88, Issue:10

    Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Diseases; Bone Marrow Failure Disorders; Child; Chronic Disease; Cyclosporine; Female; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Risk Factors; Salvage Therapy; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2013
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Myeloablative Agonists; Prospective Studies; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine

2014
Frontline therapy of severe aplastic anaemia with fludarabine, cyclophosphamide and ciclosporin.
    British journal of haematology, 2015, Volume: 171, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Vidarabine

2015
Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Prospective Studies; Republic of Korea; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult

2016
Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
    Bone marrow transplantation, 2009, Volume: 43, Issue:10

    Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Lymphocyte Depletion; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2009
Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:11

    Topics: Adolescent; Adult; Anemia, Aplastic; Antibodies, Monoclonal; Antilymphocyte Serum; Bone Marrow Transplantation; Cell Count; Child; Child, Preschool; Cyclophosphamide; Cytomegalovirus Infections; Erythrocyte Transfusion; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Leukocyte Count; Lymphoproliferative Disorders; Male; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prognosis; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2010
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
    Blood, 2011, Aug-25, Volume: 118, Issue:8

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2011
Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia.
    British journal of haematology, 2012, Volume: 157, Issue:1

    Topics: Adolescent; Adult; Anemia, Aplastic; Antigens, CD19; Antilymphocyte Serum; Antineoplastic Agents; CD3 Complex; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphocyte Depletion; Male; Myeloablative Agonists; Prospective Studies; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2012
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
    Annals of hematology, 2012, Volume: 91, Issue:9

    Topics: Adolescent; Adult; Anemia, Aplastic; Antibiotic Prophylaxis; Antilymphocyte Serum; Antiviral Agents; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Postoperative Complications; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2012
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cyclophosphamide; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2012
Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
    Bone marrow transplantation, 2005, Volume: 35, Issue:5

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cyclophosphamide; Graft Survival; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppression Therapy; Incidence; Tissue Donors; Treatment Outcome; Vidarabine

2005
Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.
    Bone marrow transplantation, 2005, Volume: 36, Issue:11

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine

2005
Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:8

    Topics: Adult; Anemia, Aplastic; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2006

Other Studies

66 other study(ies) available for vidarabine and Anemia, Aplastic

ArticleYear
Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin.
    Annals of transplantation, 2019, Aug-09, Volume: 24

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2019
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
    Stem cells and development, 2019, 10-15, Volume: 28, Issue:20

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2019
Cord blood infusion-accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia.
    International journal of hematology, 2020, Volume: 111, Issue:3

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Blood Transfusion; Child; Child, Preschool; Drug Therapy, Combination; Female; Fetal Blood; Hematopoiesis; Humans; Immunosuppressive Agents; Male; Middle Aged; Recovery of Function; Severity of Illness Index; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2020
Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide.
    Bone marrow transplantation, 2020, Volume: 55, Issue:7

    Topics: Anemia, Aplastic; Bone Marrow Transplantation; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine

2020
Fludarabine, Campath, and Low-Dose Cyclophosphamide (FCC
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:10

    Topics: Alemtuzumab; Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2020
Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Anemia, Aplastic; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2020
An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:5

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Humans; Retrospective Studies; Vidarabine; Young Adult

2021
Full Dose Cyclophosphamide with the Addition of Fludarabine for Matched Sibling Transplants in Severe Aplastic Anemia.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:10

    Topics: Adult; Anemia, Aplastic; Cyclophosphamide; Humans; Prospective Studies; Retrospective Studies; Siblings; Vidarabine

2021
Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.
    Journal of pediatric hematology/oncology, 2018, Volume: 40, Issue:4

    Topics: Adolescent; Adult; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Humans; Male; Severity of Illness Index; Survival Rate; Tissue Donors; Vidarabine

2018
Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose.
    American journal of hematology, 2018, Volume: 93, Issue:11

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation; Young Adult

2018
In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
    American journal of hematology, 2013, Volume: 88, Issue:4

    Topics: Adult; Aged; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Lymphocyte Count; Lymphocyte Depletion; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia.
    Pediatric transplantation, 2013, Volume: 17, Issue:4

    Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Blood Platelets; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Neutrophils; Retrospective Studies; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine

2013
Less could be better: the case for reducing the dose of cyclophosphamide for children undergoing allogeneic stem cell transplant for severe aplastic anemia.
    Pediatric transplantation, 2013, Volume: 17, Issue:4

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Transplantation Conditioning; Vidarabine

2013
A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia.
    International journal of hematology, 2014, Volume: 99, Issue:3

    Topics: Adolescent; Adult; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Preoperative Care; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult

2014
[Fludarabine-based increased-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Anemia, Aplastic; Child; Child, Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2014
Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG.
    Leukemia research, 2014, Volume: 38, Issue:7

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2014
[The outcome of thirteen patients with nonmalignant hematologic diseases treated with HLA haploidentical stem cell transplantation].
    Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:6

    Topics: Anemia, Aplastic; Busulfan; Graft vs Host Disease; Hematologic Diseases; Histocompatibility; HLA Antigens; Humans; Incidence; Methotrexate; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014
[Retrospective analysis of therapeutic efficacy of haploidentical allogeneic hematopoietic stem cell transplantation for severe aplastic anemia].
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:5

    Topics: Adolescent; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclosporine; Graft vs Host Disease; Haploidy; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Siblings; Survival Rate; Tissue Donors; Transplantation Conditioning; Vidarabine

2014
Reduced-dose cyclophosphamide in combination with fludarabine and anti-thymocyte globulin as a conditioning regimen for allogeneic hematopoietic stem cell transplantation for aplastic anemia.
    International journal of hematology, 2015, Volume: 101, Issue:1

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Vidarabine

2015
[Efficacies of hematopoietic stem cell transplantation for severe aplastic anemia: a report of 43 patients].
    Zhonghua yi xue za zhi, 2014, Nov-04, Volume: 94, Issue:40

    Topics: Adolescent; Adult; Anemia, Aplastic; Child; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Siblings; Transplantation Conditioning; Vidarabine; Young Adult

2014
[Efficacy of Nonmyeloablative Allogeneic Hematopoietic Stem Cells for 14 Case of Severe Acquired Aplastic Anemia].
    Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:4

    Topics: Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Mycophenolic Acid; Neutrophils; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine

2015
[Molecular diagnosis and hematopoietic stem cell transplantation in 17 children with inherited bone marrow failure syndrome].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2015, Volume: 53, Issue:11

    Topics: Anemia, Aplastic; Anemia, Diamond-Blackfan; Bone Marrow Diseases; Bone Marrow Failure Disorders; Child; Dyskeratosis Congenita; Fanconi Anemia; Fetal Blood; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Retrospective Studies; Siblings; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine

2015
[Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:12

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Methotrexate; Mycophenolic Acid; Retrospective Studies; Siblings; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine

2015
Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.
    International journal of hematology, 2016, Volume: 103, Issue:4

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Siblings; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2016
Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning.
    Bone marrow transplantation, 2016, Volume: 51, Issue:11

    Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Male; Middle Aged; Myeloablative Agonists; Siblings; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2016
[Clinical Efficacy of Haploidentical Allo-HSCT of Reduced Intensity Preconditioning Combined with Induced Immune Tolerance after Transplantation for Severe Aplastic Anemia].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:6

    Topics: Anemia, Aplastic; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Fathers; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Immune Tolerance; Male; Methotrexate; T-Lymphocyte Subsets; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2016
The combined use of Flu/ATG in nonmyeloablative SCT for severe aplastic anemia with multiple earlier transfusions.
    Bone marrow transplantation, 2009, Volume: 43, Issue:11

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine; Young Adult

2009
Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function.
    American journal of hematology, 2009, Volume: 84, Issue:3

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Myeloablative Agonists; Ovary; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2009
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting.
    Blood transfusion = Trasfusione del sangue, 2009, Volume: 7, Issue:2

    Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Donors; Busulfan; Catheter Ablation; Cost-Benefit Analysis; Cyclophosphamide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mexico; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2009
Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.
    Haematologica, 2009, Volume: 94, Issue:9

    Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Living Donors; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2009
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Child; Chronic Disease; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2009
[Female case of successful engraftment after PBSCT from her HLA-haploidentical son for severe aplastic anemia during maintenance peritoneal dialysis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:4

    Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Cyclophosphamide; Female; Graft Survival; Haploidy; HLA Antigens; Humans; Immunosuppressive Agents; Middle Aged; Nuclear Family; Peripheral Blood Stem Cell Transplantation; Peritoneal Dialysis, Continuous Ambulatory; Rabbits; Severity of Illness Index; Tacrolimus; Transplantation Conditioning; Vidarabine

2010
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.
    Haematologica, 2010, Volume: 95, Issue:6

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Europe; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2010
Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Agents; Blood Platelets; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Neutrophils; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2011
Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:1

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Drug Combinations; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Prognosis; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vidarabine; Young Adult

2011
Alternative donor marrow transplantation in children with aplastic anemia using low-dose irradiation and fludarabine-based conditioning.
    Bone marrow transplantation, 2011, Volume: 46, Issue:8

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; Male; Tissue Donors; Transplantation Conditioning; Vidarabine

2011
Antithymocyte globulin-induced acute lung injury during transplantation for aplastic anemia.
    Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:2

    Topics: Acute Lung Injury; Anemia, Aplastic; Animals; Anti-Bacterial Agents; Antilymphocyte Serum; Bacterial Infections; Bone Marrow Transplantation; Child; Cyclophosphamide; Horses; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Transplantation Conditioning; Vancomycin; Vidarabine

2011
Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival.
    Bone marrow transplantation, 2012, Volume: 47, Issue:9

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Female; Graft Rejection; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2012
Striking the right balance: optimizing conditioning regimens for unrelated donor bone marrow transplant for severe aplastic anemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:7

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; Male; Transplantation Conditioning; Vidarabine

2012
Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:4

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Cells, Cultured; Child; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Myeloablative Agonists; Secondary Prevention; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2013
Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications.
    Clinical and laboratory haematology, 2002, Volume: 24, Issue:5

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Female; Fractures, Bone; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Intellectual Disability; Male; Methylprednisolone; Mycophenolic Acid; Obesity; Peripheral Blood Stem Cell Transplantation; Prednisolone; Remission Induction; Siblings; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2002
Successful allogeneic stem cell transplantation with fludarabine-based conditioning regimen in severe aplastic anemia.
    The Journal of the Association of Physicians of India, 2003, Volume: 51

    Topics: Adult; Anemia, Aplastic; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Transplantation Conditioning; Vidarabine

2003
Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.
    Bone marrow transplantation, 2004, Volume: 34, Issue:11

    Topics: Adolescent; Anemia, Aplastic; Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Transplantation Conditioning; Vidarabine

2004
Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia.
    Bone marrow transplantation, 2005, Volume: 35, Issue:6

    Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Salvage Therapy; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Fludarabine-based conditioning used in successful bone marrow transplantation from an unrelated donor in a heavily transfused patient with severe aplastic anemia.
    International journal of hematology, 2005, Volume: 81, Issue:1

    Topics: Adolescent; Anemia, Aplastic; Blood Transfusion; Bone Marrow Transplantation; Female; Humans; Immunosuppressive Agents; Severity of Illness Index; Tissue Donors; Transplantation Conditioning; Vidarabine

2005
Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.
    Bone marrow transplantation, 2005, Volume: 35, Issue:8

    Topics: Adolescent; Adult; Anemia, Aplastic; Blood Transfusion; Bone Marrow Transplantation; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Histocompatibility; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; T-Lymphocytes; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2005
Five-month marrow aplasia in a child with refractory acute myeloid leukemia: successful management with continuous granulocyte support and reduced-intensity conditioning followed by matched unrelated bone marrow transplantation.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:4

    Topics: Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Female; Graft vs Host Disease; Granulocytes; Humans; Leukemia, Myelomonocytic, Acute; Melphalan; Neoplasm Recurrence, Local; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
    Stem cells and development, 2005, Volume: 14, Issue:2

    Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine

2005
Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
    Japanese journal of clinical oncology, 2006, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Costs and Cost Analysis; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Living Donors; Melphalan; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
Exacerbation of chronic epidural abscess following a fludarabine-based preparative regimen.
    American journal of hematology, 2006, Volume: 81, Issue:3

    Topics: Acetamides; Anemia, Aplastic; Anti-Infective Agents; Epidural Abscess; Graft vs Host Disease; Humans; Linezolid; Male; Middle Aged; Myeloablative Agonists; Oxazolidinones; Radiography; Staphylococcal Infections; Stem Cell Transplantation; Vidarabine

2006
Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    American journal of hematology, 2006, Volume: 81, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Humans; Male; Mexico; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
    Bone marrow transplantation, 2006, Volume: 37, Issue:8

    Topics: Adolescent; Adult; Anemia, Aplastic; Animals; Antigens, CD34; Antilymphocyte Serum; Cyclophosphamide; Female; Graft vs Host Disease; Horses; Humans; Immunosuppressive Agents; Male; Micropore Filters; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2006
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
    British journal of haematology, 2006, Volume: 133, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Bone Marrow Diseases; Child; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine

2006
Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.
    British journal of haematology, 2006, Volume: 133, Issue:6

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mucositis; Opportunistic Infections; Pilot Projects; Quality of Life; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2006
Unrelated donor cord blood transplantation for childhood severe aplastic anemia after a modified conditioning.
    Pediatric transplantation, 2006, Volume: 10, Issue:4

    Topics: Anemia, Aplastic; Child; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; Glucocorticoids; Graft vs Host Disease; Histocompatibility; Histocompatibility Testing; Humans; Melphalan; Myeloablative Agonists; Prednisolone; Severity of Illness Index; Time Factors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2006
Graft failure and severe autoimmune haemolysis following fludarabine-based reduced-intensity matched unrelated donor bone marrow transplantation for severe aplastic anaemia: salvage by second transplant with conventional dose conditioning.
    Bone marrow transplantation, 2006, Volume: 38, Issue:4

    Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Bone Marrow Transplantation; Female; Graft Rejection; Humans; Salvage Therapy; Tissue Donors; Vidarabine

2006
Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:9

    Topics: Aged; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2006
Conditioning with fludarabine alone and allogeneic transplantation as a successful rescue therapy for persistent, severe iatrogenic aplasia after relapse of acute myeloid leukemia.
    Bone marrow transplantation, 2007, Volume: 39, Issue:1

    Topics: Anemia, Aplastic; Female; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Leukemia, Myeloid; Middle Aged; Myeloablative Agonists; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases.
    Bone marrow transplantation, 2007, Volume: 39, Issue:7

    Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Agents; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinopathies; Humans; Immunologic Deficiency Syndromes; Infant; Male; Middle Aged; Transplantation Conditioning; Vidarabine

2007
Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    European journal of haematology, 2007, Volume: 78, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Blast Crisis; Chimera; Cord Blood Stem Cell Transplantation; Disease Progression; Fatal Outcome; Female; Graft Rejection; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Immunity, Maternally-Acquired; Isoantigens; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine

2007
Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    Bone marrow transplantation, 2007, Volume: 40, Issue:1

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Enzyme Inhibitors; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; India; Male; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.
    Haematologica, 2007, Volume: 92, Issue:5

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cause of Death; Chi-Square Distribution; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Hepatitis; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Kaplan-Meier Estimate; Living Donors; Lymphocyte Depletion; Male; Middle Aged; Proportional Hazards Models; Reoperation; Retrospective Studies; Statistics, Nonparametric; Survival Analysis; Survival Rate; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Alkylator-free conditioning regimen for patients with acquired aplastic anemia, transplanted from genetically identical twins.
    Pediatric transplantation, 2007, Volume: 11, Issue:5

    Topics: Alkylating Agents; Anemia, Aplastic; Antineoplastic Agents; Contraindications; Female; Follow-Up Studies; Humans; Male; Myeloablative Agonists; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Twins, Monozygotic; Vidarabine

2007
Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    Pediatric transplantation, 2008, Volume: 12, Issue:1

    Topics: Adolescent; Anemia, Aplastic; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Transplantation Conditioning; Vidarabine

2008
A fludarabine-based conditioning regimen for severe aplastic anemia.
    Bone marrow transplantation, 2001, Volume: 27, Issue:2

    Topics: Anemia, Aplastic; Child; Child, Preschool; Combined Modality Therapy; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Transplantation Chimera; Transplantation, Homologous; Vidarabine

2001
Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure.
    Bone marrow transplantation, 2001, Volume: 28, Issue:8

    Topics: Adult; Anabolic Agents; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Cyclosporine; Diabetes Complications; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Iron Overload; Methylprednisolone; T-Lymphocytes; Transfusion Reaction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001